Department of Medicine, Division of Rheumatology
Immune System Diseases | Musculoskeletal Diseases | Respiratory Tract Diseases | Rheumatology | Skin and Connective Tissue Diseases
OBJECTIVES: To determine the effect of hydroxychloroquine on the incidence of new respiratory infections in a large registry of rheumatoid arthritis (RA) patients compared with a matched cohort receiving other conventional disease-modifying antirheumatic drugs (csDMARDs).
METHODS: We reviewed physician-reported infections including upper respiratory infections (URI), bronchitis and pneumonia in the Corrona RA registry from June 2008 to February 2020 with the goal of comparing infections in biologic/targeted synthetic (b/ts) DMARDs naive HCQ starts compared with starts of other csDMARDs and no HCQ. Patients on different interventions were compared using time-varying adjusted Cox models adjusting for age, sex, duration of RA, BMI, disease activity, smoking status, concurrent medications, season of the year, year of onset and history of serious infections, diabetes or cardiovascular disease (CVD). A secondary analysis in a set of propensity-matched starts were also compared adjusting for time-varying covariates. The analysis was repeated including URI and bronchitis only and also for serious respiratory infections only.
RESULTS: No evidence of differences was found in the incidence of any respiratory infection (URI, bronchitis, pneumonia) in patients receiving HCQ compared with other csDMARDs: HR=0.87 (0.70 to1.07) in adjusted analyses and HR=0.90 (0.70 to 1.17) in adjusted matched analysis. Similar results were found in the analysis of URI and bronchitis only and for serious respiratory infections only.
CONCLUSIONS: In patients with RA, the risk for respiratory infections was similar among patients using HCQ as compared to other non-biologic DMARDs.
Arthritis, Epidemiology, Hydroxychloroquine, Rheumatoid, SARS-CoV-2, COVID-19
Rights and Permissions
© Author(s) (or their employer(s)) 2020. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
DOI of Published Version
Kremer JM, Reed G, Pappas DA, Harold LR, Kane K, Greenberg J, Winthrop K. Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open. 2020 Nov;6(3):e001389. doi: 10.1136/rmdopen-2020-001389. PMID: 33161375. Link to article on publisher's site
Kremer JM, Reed GW, Pappas DA, Harrold LR, Kane KJ, Greenberg J, Winthrop K. (2020). Hydroxychloroquine and the risk of respiratory infections among RA patients. Open Access Publications by UMMS Authors. https://doi.org/10.1136/rmdopen-2020-001389. Retrieved from https://escholarship.umassmed.edu/oapubs/4480
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License